David E Moller Selected Research

David E Moller Research Topics

Disease

21	Type 2 Diabetes Mellitus (MODY) 11/2021 - 03/2002
12	Insulin Resistance 01/2022 - 03/2002
10	Obesity 06/2014 - 04/2003
7	Body Weight (Weight, Body) 01/2023 - 11/2004
7	Hyperglycemia 09/2006 - 03/2003
6	Dyslipidemias (Dyslipidemia) 01/2022 - 01/2002
5	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 04/2003
4	Non-alcoholic Fatty Liver Disease 01/2023 - 11/2021
4	Inflammation (Inflammations) 01/2022 - 01/2002
3	Hypertriglyceridemia 01/2005 - 03/2003
3	Atherosclerosis 03/2003 - 01/2002
2	Alcoholic Fatty Liver 01/2023 - 11/2021
2	Renal Insufficiency (Renal Failure) 01/2023 - 01/2022
2	Demyelinating Diseases (Demyelinating Disease) 01/2022 - 01/2002
2	Adrenoleukodystrophy (Adrenoleukodystrophy, X-Linked) 01/2022 - 01/2022
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2022 - 01/2021
2	Fatty Liver 12/2021 - 12/2008
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2013 - 06/2007
2	Cardiomegaly (Heart Hypertrophy) 09/2006 - 10/2003
2	Hypertrophy 11/2004 - 05/2003
1	Disease Progression 01/2023
1	Cysts 01/2023
1	Fibrosis (Cirrhosis) 01/2023
1	Kidney Diseases (Kidney Disease) 01/2023
1	Autosomal Dominant Polycystic Kidney (ADPKD) 01/2023
1	Hyperlactatemia 01/2022
1	Lactic Acidosis 01/2022
1	Rare Diseases (Rare Disease) 01/2022
1	Overweight 12/2021
1	Hypoglycemia (Reactive Hypoglycemia) 07/2016
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 10/2013
1	Edema (Dropsy) 07/2009
1	Weight Gain 07/2009
1	Heart Failure 07/2009
1	Thrombosis (Thrombus) 06/2007
1	Hypertension (High Blood Pressure) 01/2005
1	Glucose Intolerance 01/2005
1	Hyperinsulinism (Hyperinsulinemia) 05/2004
1	Vascular Diseases (Vascular Disease) 04/2003

Drug/Important Bio-Agent (IBA)

8	PPAR gammaIBA 07/2009 - 03/2002
7	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 05/2003
5	2- chloro- 3- (1- hydroxy- 5,6,7,8- tetrahydronaphthalen- 2- yl)- 6- oxo- 5- phenyl- 7H- thieno)(2,3- b)pyridin- 4- olate potassiumIBA 01/2023 - 11/2021
5	Insulin (Novolin)FDA Link 09/2013 - 03/2002
5	Triglycerides (Triacylglycerol)IBA 09/2013 - 03/2003
4	imegliminIBA 01/2022 - 01/2021
4	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 02/2006
4	fibroblast growth factor 21IBA 09/2013 - 12/2008
4	PPAR alphaIBA 09/2006 - 10/2003
4	LipidsIBA 04/2005 - 03/2003
3	Adenylate KinaseIBA 01/2022 - 11/2021
3	adomeglivantIBA 01/2017 - 07/2016
3	Glucagon Receptors (Glucagon Receptor)IBA 01/2017 - 07/2016
3	Nonesterified Fatty Acids (NEFA)IBA 06/2006 - 11/2004
3	Streptozocin (Streptozotocin)FDA Link 06/2006 - 03/2002
3	Rosiglitazone (Avandia)FDA Link 08/2003 - 03/2003
2	Pioglitazone (Actos)FDA Link 01/2023 - 05/2004
2	Metformin (Glucophage)FDA LinkGeneric 01/2022 - 07/2002
2	Glucagon (Glukagon)FDA Link 07/2016 - 10/2013
2	LY2405319IBA 09/2013 - 01/2013
2	HDL CholesterolIBA 09/2013 - 01/2005
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 09/2006 - 01/2002
2	PPAR-gamma AgonistsIBA 09/2006 - 11/2004
2	CholesterolIBA 08/2005 - 07/2002
2	2,4-thiazolidinedione (thiazolidinedione)IBA 11/2004 - 04/2003
2	ThiazolidinedionesIBA 08/2002 - 01/2002
1	Urea (Carbamide)FDA LinkGeneric 01/2023
1	polycystic kidney disease 1 proteinIBA 01/2023
1	Phosphotransferases (Kinase)IBA 01/2023
1	procollagen Type III-N-terminal peptide (PIIP)IBA 01/2023
1	Deamino Arginine Vasopressin (Desmopressin)FDA LinkGeneric 01/2023
1	ColforsinIBA 01/2023
1	Adenosine Monophosphate (AMP)IBA 01/2023
1	nasIBA 01/2023
1	Member 1 Subfamily D ATP Binding Cassette TransporterIBA 01/2022
1	BiguanidesIBA 01/2022
1	DeuteriumIBA 01/2022
1	Gentamicins (Gentamicin)FDA LinkGeneric 01/2022
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2022
1	ElementsIBA 01/2021
1	IncretinsIBA 10/2013
1	LDL CholesterolIBA 09/2013
1	ApolipoproteinsIBA 09/2013
1	AdiponectinIBA 09/2013
1	antineoplaston A10 (A 10)IBA 01/2013
1	Butyric Acid (Butanoic Acid)IBA 07/2009
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 06/2007
1	Plasminogen Activators (Plasminogen Activator)IBA 06/2007
1	CytokinesIBA 06/2007
1	Glycoproteins (Glycoprotein)IBA 06/2007
1	Sitagliptin Phosphate (Januvia)FDA Link 06/2006
1	Dipeptidyl-Peptidase IV InhibitorsIBA 06/2006
1	Fenofibrate (CiL)FDA LinkGeneric 08/2005
1	AcidsIBA 04/2005
1	LeptinIBA 11/2004
1	Hypoglycemic Agents (Hypoglycemics)IBA 06/2004
1	MK0767IBA 05/2004
1	Glucagon-Like Peptide 1 (GLP 1)IBA 05/2003
1	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 05/2003

Therapy/Procedure

8	Therapeutics 01/2022 - 04/2003
1	Glycemic Control 06/2006